02:50 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

Rethinking definitions of autoimmune disease

The autoimmune field is dialing up its search for better biomarkers as it seeks to make the next step change from the targeted therapies that overtook blanket immunosuppressants. The question is whether autoimmunity might follow...
22:41 , Sep 13, 2018 |  BC Week In Review  |  Clinical News

Higher doses of BMS's psoriasis candidate hit Phase II efficacy mark

Bristol-Myers Squibb Co. (NYSE:BMY) said four of five doses of BMS-986165 met the primary endpoint in the Phase II IM011-011 trial to treat moderate to severe plaque psoriasis. The compound, an oral tyrosine kinase 2...
14:08 , Sep 12, 2018 |  BC Extra  |  Clinical News

Higher doses of BMS's psoriasis candidate hit Phase II efficacy mark

Bristol-Myers Squibb Co. (NYSE:BMY) said four of five doses of BMS-986165 met the primary endpoint in the Phase II IM011-011 trial to treat moderate to severe plaque psoriasis. The compound, an oral tyrosine kinase 2...
22:08 , Oct 5, 2017 |  BC Innovations  |  Product R&D

Nimble move

Celgene Corp. ’s deal with Nimbus Therapeutics LLC is another vote of confidence that Nimbus’ computational drug design technology can solve druggability problems that trip up standard medicinal chemistry. The partnership gives Celgene access to...